{"id":2016,"date":"2025-09-22T12:51:06","date_gmt":"2025-09-22T12:51:06","guid":{"rendered":"https:\/\/www.europesays.com\/ee\/2016\/"},"modified":"2025-09-22T12:51:06","modified_gmt":"2025-09-22T12:51:06","slug":"voidujooks-kaalulangetusravimitele-pfizer-ostab-73-miljardiga-uue-polvkonna-ravimifirma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ee\/2016\/","title":{"rendered":"V\u00f5idujooks kaalulangetusravimitele: Pfizer ostab 7,3 miljardiga uue p\u00f5lvkonna ravimifirma"},"content":{"rendered":"<p>Ravimifirma Pfizer on valmis maksma Metsera aktsia eest 47,50 dollarit sularahas ning lisaks veel 22,50 dollarit aktsia kohta, kui ettev\u00f5tte ravimiarendus saavutab teatud kindlaksm\u00e4\u00e4ratud eesm\u00e4rgid. Seega v\u00f5ib tehingu koguv\u00e4\u00e4rtus ulatuda 7,3 miljardi dollarini, mis on m\u00e4rkimisv\u00e4\u00e4rne preemia v\u00f5rreldes Metsera reede\u00f5htuse sulgemishinnaga New Yorgi b\u00f6rsil (33,32 dollarit).<\/p>\n<p class=\"ng-star-inserted\">Asjaga kursis olevate allikate s\u00f5nul v\u00f5idakse tehingust teatada juba esmasp\u00e4eval, kui viimasel hetkel ei teki takistusi.<\/p>\n<p class=\"ng-star-inserted\">Pfizerile pakub see tehing elut\u00e4htsat v\u00f5imalust siseneda uue p\u00f5lvkonna kaalulangetusravimite lahingusse, eriti kuna nende endi v\u00e4ljat\u00f6\u00f6tatud samalaadne ravim danuglipron kukkus t\u00e4navu kliinilistes katsetes l\u00e4bi. <\/p>\n<p class=\"ng-star-inserted\">Tegevjuht Albert Bourla juhtimisel on Pfizer p\u00fc\u00fcdnud leida uusi kasvumootoreid, et t\u00f5sta ettev\u00f5tte aktsiahinda, mis on langenud enam kui poole v\u00f5rra v\u00f5rreldes 2021. aasta koroonapandeemia tippajaga. Eelmisel aastal ostis Pfizer 43 miljardi dollari eest v\u00e4hiravile keskendunud biotehnoloogiafirma Seagen, kuid investorid pole siiani ettev\u00f5tte tuleviku osas liialt optimistlikud.<\/p>\n<p>Huvilisi oli rohkem<\/p>\n<p class=\"ng-star-inserted\">T\u00e4navu edukalt b\u00f6rsile tulnud Metsera on \u00fcks paljudest lootustandvatest biotehnoloogiafirmadest, mis uurib uue p\u00f5lvkonna kaalulangetusravimeid. Nende eesm\u00e4rk on murda turuliidrite Eli Lilly ja Novo Nordiski domineerimine. M\u00f5lema praeguse menuravimiga on seostatud k\u00f5rvaltoimeid, n\u00e4iteks lihasmassi kadu, mida uue p\u00f5lvkonna ravimitega p\u00fc\u00fctakse v\u00e4ltida.<\/p>\n<p class=\"ng-star-inserted\">Allikate s\u00f5nul tunti Metsera vastu laialdast huvi ning Pfizer pidi ettev\u00f5tte nimel konkurentsitihedas enampakkumises teistest \u00fcle pakkuma.<\/p>\n<p class=\"ng-star-inserted\">Anal\u00fc\u00fctikud prognoosivad, et rasvumisravimite turu v\u00e4\u00e4rtus v\u00f5ib tippaegadel ulatuda 95 miljardi dollarini aastas. Ka teised suured ravimifirmad on turul aktiivsed \u2013 n\u00e4iteks \u0160veitsi ravimihiid Roche on hiljuti teinud miljarditehinguid Taani biotehnoloogiafirma Zealand Pharma ja USA ettev\u00f5tte Carmot Therapeutics omandamiseks.<\/p>\n<p class=\"ng-star-inserted\">Metsera k\u00f5ige paljulubavam ravimikandidaat MET-097i n\u00e4itas teise faasi uuringus 12 n\u00e4dalaga 11,3%-list kehakaalu langust ning seda piiratud k\u00f5rvalm\u00f5judega. Lisaks arendab ettev\u00f5te pikatoimelist, kord kuus s\u00fcstitavat versiooni, mis muudaks ravimi patsientidele oluliselt mugavamaks.<\/p>\n","protected":false},"excerpt":{"rendered":"Ravimifirma Pfizer on valmis maksma Metsera aktsia eest 47,50 dollarit sularahas ning lisaks veel 22,50 dollarit aktsia kohta,&hellip;\n","protected":false},"author":2,"featured_media":2017,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[14],"tags":[131,130,37,33,35,34,36,2121,2120,514],"class_list":["post-2016","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ari","tag-ari","tag-business","tag-ee","tag-eesti","tag-eesti-keel","tag-estonia","tag-estonian","tag-kaalulangetamine","tag-kaalulangetus","tag-pfizer"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/2016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/comments?post=2016"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/2016\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media\/2017"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media?parent=2016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/categories?post=2016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/tags?post=2016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}